1. Home
  2. CCNE vs DSGN Comparison

CCNE vs DSGN Comparison

Compare CCNE & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNB Financial Corporation

CCNE

CNB Financial Corporation

SELL

Current Price

$33.38

Market Cap

1.0B

Sector

Finance

ML Signal

SELL

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.71

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCNE
DSGN
Founded
1865
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
853.8M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
CCNE
DSGN
Price
$33.38
$9.71
Analyst Decision
Buy
Strong Buy
Analyst Count
6
8
Target Price
★ $38.00
$21.71
AVG Volume (30 Days)
116.6K
★ 638.8K
Earning Date
10-29-2026
11-04-2026
Dividend Yield
★ 2.25%
N/A
EPS Growth
★ 4.18
N/A
EPS
★ 1.79
N/A
Revenue
N/A
N/A
Revenue This Year
$25.41
N/A
Revenue Next Year
$5.38
N/A
P/E Ratio
$18.87
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.90
$5.28
52 Week High
$36.17
$17.25

Technical Indicators

Market Signals
Indicator
CCNE
DSGN
Relative Strength Index (RSI) 44.24 23.20
Support Level $32.84 N/A
Resistance Level $35.06 $10.17
Average True Range (ATR) 0.62 0.65
MACD -0.01 -0.21
Stochastic Oscillator 36.51 8.22

Price Performance

Historical Comparison
CCNE
DSGN

About CCNE CNB Financial Corporation

CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: